Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease

Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease.BackgroundEnd-stage renal disease (ESRD) patients undergoing hemodialysis treatment have reduced plasma L-carnitine levels; however, the relationship between dialysis age and carnitine status is poorly understood. This study examined the relationship between duration of dialysis and plasma and skeletal muscle concentrations of L-carnitine and its esters in ESRD patients.MethodsBlood samples were collected from 21 patients at baseline and throughout the first 12 months of hemodialysis. In 5 patients, muscle samples were obtained after 0, 6, and 12 months of hemodialysis. Blood and muscle samples were collected from an additional 20 patients with a mean dialysis age of 5.10 years. L-carnitine, acetyl-L-carnitine, and total L-carnitine were measured by high-performance liquid chromatography (HPLC).ResultsThe mean ± SD plasma L-carnitine concentration in ESRD patients who had not yet started hemodialysis was 50.6 ± 20.0 μmol/L. Significantly lower concentrations were observed after 12 months (29.7 ± 10.5 μmol/L) and >12 months (22.0 ± 5.4 μmol/L) of hemodialysis treatment. Acetyl-L-carnitine also declined with dialysis age, while plasma nonacetylated acylcarnitines continued to increase with the progression of hemodialysis therapy. An inverse relationship between dialysis age and muscle L-carnitine concentrations was observed.ConclusionLong-term hemodialysis treatment is associated with a significant reduction in endogenous plasma and muscle L-carnitine levels and a significant increase in plasma acylcarnitines. The majority of the change in plasma L-carnitine concentrations occurs within the first few months of hemodialysis, while muscle levels continue to decline after 12 months of treatment